Zacks: Analysts Expect CytomX Therapeutics Inc (NASDAQ:CTMX) to Announce -$0.55 EPS

Equities analysts expect CytomX Therapeutics Inc (NASDAQ:CTMX) to post earnings per share of ($0.55) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for CytomX Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.74). CytomX Therapeutics posted earnings of ($0.35) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 57.1%. The firm is expected to report its next quarterly earnings results after the market closes on Wednesday, August 7th.

According to Zacks, analysts expect that CytomX Therapeutics will report full year earnings of ($2.10) per share for the current fiscal year, with EPS estimates ranging from ($2.92) to ($1.67). For the next year, analysts expect that the company will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.73) to ($1.99). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.22. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. The firm had revenue of $29.49 million for the quarter, compared to analysts’ expectations of $13.59 million.

A number of equities analysts have commented on the stock. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. BidaskClub cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Mizuho reaffirmed a “buy” rating and set a $16.00 price target on shares of CytomX Therapeutics in a research note on Monday. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating and set a $14.00 price target for the company in a research note on Wednesday, July 17th. Finally, Nomura dropped their price target on shares of CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $20.22.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aperio Group LLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $70,000. BNP Paribas Arbitrage SA grew its holdings in shares of CytomX Therapeutics by 84,072.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 9,248 shares during the period. Legal & General Group Plc grew its holdings in shares of CytomX Therapeutics by 18.6% during the 4th quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 1,306 shares during the period. Deltec Asset Management LLC purchased a new stake in shares of CytomX Therapeutics during the 1st quarter worth about $129,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of CytomX Therapeutics by 376.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 10,650 shares during the period. Institutional investors own 81.81% of the company’s stock.

Shares of NASDAQ:CTMX traded down $0.22 during trading on Wednesday, reaching $10.31. 283,288 shares of the stock traded hands, compared to its average volume of 439,301. The firm’s 50-day moving average price is $11.00. CytomX Therapeutics has a 52-week low of $8.94 and a 52-week high of $27.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21. The company has a market capitalization of $461.27 million, a PE ratio of -5.08 and a beta of 0.64.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Further Reading: Why is the ROA ratio important?

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.